Please assess the completion status of the following clinical trial:

Trial Title: Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Low Back Pain \> 3/10~* Pain \> 1 year~* Degenerative disc disease as seen on magnetic resonance imaging (MRI), which must meet minimum disc grading criteria: at least a grade III disc degeneration, a hyperintense zone, or abnormal disc morphology.~* Patients who may have had back surgery will be included.~* No epidural steroids or other nerve blocks for back pain either two weeks before or during the study period.~* No opioids or on short-acting opioids only (max. daily amount=120 mg morphine equivalents). It is not feasible to recruit only opioid naive patients.~* Must agree to 2-week washout for those on opioids.~* No active substance abuse.~* No intention to take new pain or psychiatric treatments during the study, including chiropractic, physical therapy, or complementary or alternative treatments (CAM). It is not feasible to take participants off of any other pain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDS).~* No pregnancy or the intent to become pregnant during the study, and no nursing mothers.~* Women, who are able to bear children, must agree to use contraceptives throughout the study.~* In men, normal baseline testosterone levels.~Exclusion Criteria:~* Patients with pain due to disorders not including a component of disc degeneration, or those with unknown causes of pain will be excluded.~* Patients with the intent to undergo back surgery will be excluded.~* Patients with a history of recent or ongoing alcohol or other drug addiction disorders will be excluded.~* Patients with any history of substance abuse of opioids will be excluded.~* Patients whose diagnosis cannot be firmly established according to criteria described above would not be included.~* Patients whose medical and psychiatric comorbidities are not well controlled, or who are currently experiencing an acute exacerbation of the medical comorbidity, will be excluded.~* Males with abnormal testosterone levels will be excluded (normal range is 1800-6650 pg/ml).~* Female patients who nursing will be excluded.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Low Negative Affect (NA) (Type: ACTIVE_COMPARATOR): Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
- Moderate NA (Type: ACTIVE_COMPARATOR): Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
- High NA (Type: ACTIVE_COMPARATOR): Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).